Navigation Links
Risks/Benefits of Osteoporosis Drug Use in Postmenopausal Women

The drug may help prevent breast cancer and vertebral fractures, but raise the risk of blood clots and fatal strokes.//

A study in the July 13 issue of the New England Journal of Medicine, reporting the results of a 5-1/2 year-long trial of more than 10,000 postmenopausal women with a history of heart disease or at high risk for heart disease, shows that patients given raloxifene therapy had a reduced incidence of vertebral fractures and breast cancer, but an increased incidence of blood clots and fatal strokes. The multi-site international study was headed by Elizabeth Barrett-Connor, M.D., Professor of Family and Preventive Medicine at the University of California, San Diego (UCSD) School of Medicine.

The study showed mixed results. On the positive side, raloxifene therapy reduced invasive breast cancer by 44 percent with 1.2 fewer cases per 1000 women treated for one year. Raloxifene has anti-estrogenic effects in the breast, inhibiting the growth of estrogen-stimulated breast cancer. It also reduced painful vertebral fractures by 35% with 1.3 fewer cases per 1000 women.

On the other hand, use of raloxifene was shown to raise the risk of blood clots by 44%, or 1.2 cases per 1000 women treated for one year. Additionally, 59 of the 5,044 raloxifene users had fatal strokes, compared to only 39 of the half on placebo, an absolute increase of 0.7 cases per 1000 women treated for one year, or a 49 percent greater risk of stroke-related death – though there was no significant difference in the total number of stroke episodes.

“The breast cancer prevention benefits may not justify the risks of taking raloxifene for some patients, especially those already prone to heart problems, because of the risk related to other diseases,” said Barrett-Connor, who added that women should talk about risks with their doctors.

Doctors had thought that the drug might help prevent heart problems, because it lowers cholesterol leve ls. However, the study showed that raloxifene therapy did not significantly reduce the risk of coronary events such as heart attack, hospitalization or death in the clinical trial group assigned to raloxifene therapy, made up of women with previous established or proven risk of heart disease.

Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) produced by Eli Lilly. The drug is sold as Evista for preventing and treating osteoporosis, and has also been tested by doctors as an alternative to tamoxifen for preventing breast cancer in a previous trial.

The Raloxifene Use for the Heart (RUTH) trial began in 1998 to determine the effects of the drug on clinical coronary events in women with or at increased risk for coronary heart disease. Eligible participants were women age 55 years or older, who were at least one year postmenopausal, and had established or risk factors for heart disease such as clogged arteries, high blood pressure or cholesterol level, smoking or diabetes. Women at 177 sites in 26 countries were randomly assigned to treatment or placebo.

After an average of five years, the RUTH study showed that deaths and major heart problems were about the same in both the group receiving raloxifene and those taking a placebo. Raloxifene users experienced one-third fewer cases of breast cancer and about half the number of invasive breast cancers.

(Source: Newswise
'"/>




Related medicine news :

1. New treatment for Osteoporosis
2. Osteoporosis in men
3. Osteoporosis Drugs: right time to take-off
4. Fluoride Found Effective in Osteoporosis
5. Mutation connected to Osteoporosis
6. Osteoporosis associated with Childhood Cancer
7. A treatment for Osteoporosis
8. Osteoporosis could be caused by irregular periods
9. Back exercises reduces Osteoporosis
10. Osteoporosis and kidney stones gene marker identified
11. The Answer To Prevent Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of two biometric time and attendance tracking products: the new NCheck Cloud Bio ... Cloud Bio Attendance uses biometric face recognition to enable users to check in ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... direct measurement of corrosive ions found in power plant water and steam. , ... such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is ... dentists should be aware of when utilizing dental laboratories and technicians that create ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... ALBANY, New York , March 28, 2017 /PRNewswire/ ... features a largely consolidated vendor landscape, with the top ... and Agilent Technologies accounting for a significant 49% of ... in a recent report. The vendor landscape is intensely ... large share in the overall market. These factors have ...
(Date:3/28/2017)... 2017 This morning,s research ... stocks: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals ... and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN ... space which is governed by the same governing ... the industry are wholesalers, retailers, pharmacies, and benefit ...
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary of ... the company,s board of directors: ... Mr. Gabrieli will serve as chairman of the board of ... chief commercial officer of Forest Laboratories. ... Partners. "We are excited to announce ...
Breaking Medicine Technology: